Preclinical models for precision oncology

Maider Ibarrola-Villava, Andrés Cervantes, Alberto Bardelli

Research output: Contribution to journalReview articlepeer-review


Precision medicine approaches have revolutionized oncology. Personalized treatments require not only identification of the driving molecular alterations, but also development of targeted therapies and diagnostic tests to identify the appropriate patient populations for clinical trials and subsequent therapeutic implementation. Preclinical in vitro and in vivo models are widely used to predict efficacy of newly developed treatments. Here we discuss whether, and to what extent, preclinical models including cell lines, organoids and tumorgrafts recapitulate key features of human tumors. The potential of preclinical models to anticipate treatment efficacy and clinical benefit is also presented, using examples in different tumor types.

Original languageEnglish
Pages (from-to)239-246
Number of pages8
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Issue number2
Publication statusPublished - Dec 1 2018


  • Organoids
  • Patient-derived xenografts (PDX)
  • Preclinical models

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research


Dive into the research topics of 'Preclinical models for precision oncology'. Together they form a unique fingerprint.

Cite this